
According to Benzinga Pro data, during Q4, Caribou Biosciences (NASDAQ:CRBU) posted sales of $2.56 million. Earnings were up 11.9%, but Caribou Biosciences still reported an overall loss of $18.48 million. Caribou Biosciences collected $3.98 million in revenue during Q3, but reported earnings showed a $20.97 million loss.